BRIEF-Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star

BRIEF-Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star - FT

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Incyte Nears Up To $2 Billion Deal For Blood Disorder Biotech Star - FT

Jun 7, 2026 3:23 AM

June 7 (Reuters) -

* INCYTE NEARS UP TO $2BN DEAL FOR BLOOD DISORDER BIOTECH

STAR - FT

Source text: [https://tinyurl.com/4fdjr644]

Further company coverage:

Previous page： Sable Offshore Disputes Hunterbrook's Claims on Accounts, Bonding Next page： Jet.AI Q3 revenue falls 56%, operating loss narrows

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sable Offshore Disputes Hunterbrook's Claims on Accounts, Bonding

Nov 14, 2025

04:42 PM EST, 11/14/2025 (MT Newswires) -- Sable Offshore ( SOC ) on Friday disputed certain inaccuracies in a report by investment firm Hunterbrook regarding its accounts payable, ownership and bonding requirements with ExxonMobil ( XOM ) . The company clarified that its accounts payable as of September 30, was approximately $53 million, not the $163 million cited in Hunterbrook's...

Jet.AI Q3 revenue falls 56%, operating loss narrows

Nov 14, 2025

Overview * Jet.AI ( JTAI ) Q3 revenue declines to $1.7 mln from $3.9 mln last year * Company reports operating loss of $2 mln, an improvement from $2.9 mln last year * Jet.AI ( JTAI ) progresses on Canadian Hyperscale Data Center Project, completing second milestone Outlook * Jet.AI ( JTAI ) prioritizes completing third milestone of Canadian data...

Beam Global Q3 revenue misses estimates

Nov 14, 2025

Overview * Beam Global ( BEEM ) Q3 revenue fell 50% yr/yr, missing analyst expectations * Net loss for Q3 missed analyst estimates * Company expanded into Middle East with new joint venture Outlook * Beam Global ( BEEM ) anticipates growth from Middle East expansion due to $1 trillion infrastructure investment, in the next decade * Company expects revenue...

Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.

Nov 14, 2025

- Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - - Additional portfolio monetization efforts continue - - Company reports 3Q 2025 financial results - - $112.6 million in cash and cash equivalents and marketable securities as of September 30,...